This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keefe, D. L. Search for Related Content PubMed PubMed Citation Articles by Keefe, D. L.

The Cardiotoxic Potential of the 5-HT₃ Receptor Antagonist Antiemetics: Is There Cause for Concern?

Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Deborah L. Keefe, M.D., M.PH., Cardiology and Critical Care Services, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Current address: P.O. Box 500, New Rochelle, New York 10804-0500, USA. e-mail: dkclinpharm{at}aol.com

Purpose. To review and evaluate the potential cardiac effects of 5-HT₃ antiemetic treatment in patients who may be predisposed to cardiac complications resulting from malignancy, cytotoxic oncologic regimens, or preexisting comorbid conditions.

Design. A literature review was conducted on the negative cardiovascular effects of chemotherapeutic agents, and, more specifically, on the cardiac interactions of the 5-HT₃ receptor antagonists commonly used to treat chemotherapy-induced nausea and vomiting.

Results. Clinical studies in healthy subjects have reported electrocardiograph changes following administration of 5-HT₃ receptor antagonists. However, there are limited data on the use of 5-HT₃ antiemetics when administered with cardiotoxic chemotherapy. Nonetheless, the development of significant electrocardiograph changes with some agents may indicate a potential for significant cardiac effects in patients, particularly those who may be predisposed to cardiac complication.

Conclusions. As the predicted human life span increases, clinicians will be treating a larger, older oncology population. Because two of the most common major comorbidities are cardiovascular related, we need to be acutely aware of the toxic effects of chemotherapy, as well as the possible cardiac interaction of supportive agents, specifically the 5-HT₃ antiemetics. Until more data are made available, the best antiemetic option for patients receiving emetogenic and cardiotoxic chemotherapy may be the agent with the fewest apparent cardiac effects.

Key Words. Cardiotoxicity • 5-HT₃ antiemetics • Granisetron • Ondansetron • Dolasetron

This article has been cited by other articles:

				R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773. [Abstract] [Full Text] [PDF]

				I. Oztop, M. Gencer, T. Okan, A. Yaren, E. Altekin, S. Turker, and U. Yilmaz Evaluation of Cardiotoxicity of a Combined Bolus plus Infusional 5-Fluorouracil/Folinic Acid Treatment by Echocardiography, Plasma Troponin I Level, QT Interval and Dispersion in Patients with Gastrointestinal System Cancers Jpn. J. Clin. Oncol., May 1, 2004; 34(5): 262 - 268. [Abstract] [Full Text] [PDF]

				A. J Coop Comment: electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists Ann. Pharmacother., December 1, 2003; 37(12): 1918 - 1918. [Full Text] [PDF]

				P. Ellis and N. Dozier Evidence for Equivalent Electrocardiographic Changes Among the 5-HT3 Receptor Antagonists Oncologist, April 1, 2003; 8(2): 216 - 218. [Full Text] [PDF]

				S. Goodin and R. Cunningham In Reply: Evidence for Equivalent Cardiotoxicity of the 5-HT3 Receptor Antagonists Oncologist, April 1, 2003; 8(2): 219 - 221. [Full Text] [PDF]